The qEEG Signature of Selective NMDA NR2B Negative Allosteric Modulators; A Potential Translational Biomarker for Drug Development

Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains

(2015) Michael R Weed et al.   NEUROPSYCHOPHARMACOLOGY

Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

(2014) Gerard Sanacora et al.   NEUROPSYCHOPHARMACOLOGY

NR2B Antagonist CP-101,606 Abolishes Pitch-Mediated Deviance Detection in Awake Rats

(2014) Digavalli V. Sivarao et al.   Frontiers in Psychiatry

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects

(2013) G Sanacora et al.   MOLECULAR PSYCHIATRY

Nonhuman primate model of schizophrenia using a noninvasive EEG method

(2013) R. Gil-da-Costa et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression

(2012) Carlos A. Zarate et al.   BIOLOGICAL PSYCHIATRY

Differential Role of NR2A and NR2B Subunits in N-Methyl-D-Aspartate Receptor Antagonist-Induced Aberrant Cortical Gamma Oscillations

(2011) Bernat Kocsis   BIOLOGICAL PSYCHIATRY

Emerging role of glutamate in the pathophysiology of major depressive disorder

(2009) Kenji Hashimoto   BRAIN RESEARCH REVIEWS

Gamma and Delta Neural Oscillations and Association with Clinical Symptoms under Subanesthetic Ketamine

(2009) L Elliot Hong et al.   NEUROPSYCHOPHARMACOLOGY

Glutamate-based antidepressants: 20 years on

(2009) Phil Skolnick et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

(2008) Sheldon H. Preskorn et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Neurophysiological biomarkers for drug development in schizophrenia

(2007) Daniel C. Javitt et al.   NATURE REVIEWS DRUG DISCOVERY